mna-715 and triptolide

mna-715 has been researched along with triptolide* in 1 studies

Reviews

1 review(s) available for mna-715 and triptolide

Article	Year
New drugs to improve transplant outcomes. Transplantation, 2004, May-15, Volume: 77, Issue:9 Suppl Fujisawa is committed to improving the outcomes of transplant patients worldwide. Research and development programs are underway for a new modified release dosage form of tacrolimus (MR-4), a new analog of leflunomide (FK 778), and several novel compounds (PG 490-88, AGI 1096) in collaboration with other companies. These programs are targeted to address many of the unmet medical needs in transplantation including (1) improving compliance, (2) reducing chronic rejection, and (3) improving long-term safety by reducing infectious and cardiovascular risk. Topics: Alkynes; Animals; Delayed-Action Preparations; Diterpenes; Epoxy Compounds; Graft Rejection; Humans; Immunosuppressive Agents; Isoxazoles; Nitriles; Phenanthrenes; Probucol; Tacrolimus	2004

Article

Year

New drugs to improve transplant outcomes.

Transplantation, 2004, May-15, Volume: 77, Issue:9 Suppl

Fujisawa is committed to improving the outcomes of transplant patients worldwide. Research and development programs are underway for a new modified release dosage form of tacrolimus (MR-4), a new analog of leflunomide (FK 778), and several novel compounds (PG 490-88, AGI 1096) in collaboration with other companies. These programs are targeted to address many of the unmet medical needs in transplantation including (1) improving compliance, (2) reducing chronic rejection, and (3) improving long-term safety by reducing infectious and cardiovascular risk.

Topics: Alkynes; Animals; Delayed-Action Preparations; Diterpenes; Epoxy Compounds; Graft Rejection; Humans; Immunosuppressive Agents; Isoxazoles; Nitriles; Phenanthrenes; Probucol; Tacrolimus

2004